19:19 , Jun 8, 2018 |  BC Week In Review  |  Clinical News

BlackThorn brings KOR antagonist into clinic

BlackThorn Therapeutics Inc. (San Francisco, Calif.) began a Phase I trial evaluating up to seven single and multiple ascending doses of BTRX-335140 to assess dose exposure and safety in about 90 healthy volunteers. The company...
20:48 , Jul 28, 2017 |  BioCentury  |  Product Development

Circuit logic

BlackThorn Therapeutics Inc. has begun the first of a series of studies that will test whether it can solve a tough problem in neurological drug development: the tendency of heterogeneity among patients with the same...